Spyre tumbles as immune drug misses mark in rheumatoid arthritis
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
Biopharmaceutical company - Antibodies
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data